SureTrader SPDR Advertisement
Home > Boards > US Listed > Biotechs > Ariad Pharmaceuticals, Inc. (ARIA)

A relevant excerpt from the patent application:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
iandy Member Profile
Member Level 
Followed By 12
Posts 2,756
Boards Moderated 1
Alias Born 06/09/10
160x600 placeholder
Advertisement
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/27/2015 4:40:19 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/24/2015 4:08:40 PM
ARIAD to Webcast Conference Call on Second Quarter 2015 Financial Results "Business Wire" - 7/22/2015 7:35:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/16/2015 5:41:07 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/16/2015 5:35:52 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/16/2015 5:27:03 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/16/2015 5:15:46 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/16/2015 5:13:36 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/16/2015 5:12:17 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/16/2015 5:09:35 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/16/2015 4:23:15 PM
Equity Coverage on Biotechnology -- Aeterna Zentaris, Ariad Pharma, AVEO Pharma, Aduro BioTech, and 22nd Century Group "PR Newswire (US)" - 7/16/2015 9:10:00 AM
Confidential Treatment Order (ct Order) "Edgar (US Regulatory)" - 7/14/2015 5:08:35 PM
Proxy Statement (definitive) (def 14a) "Edgar (US Regulatory)" - 6/25/2015 4:08:06 PM
ARIAD rende noti i dati sulla sicurezza e l'efficacia a lungo termine di Ponatinib ottenuti da uno studio clinico Pace di fas... "Business Wire" - 6/17/2015 7:17:00 PM
ARIAD met à jour les données de tolérance et d'efficacité à long terme du ponatinib,provenant de l'essai clinique de pha... "Business Wire" - 6/16/2015 12:34:00 PM
ARIAD legt langfristige Sicherheits- und Wirksamkeitsdaten zu Ponatinib aus klinischer Phase-2-Studie PACE vor "Business Wire" - 6/14/2015 8:53:00 AM
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial "Business Wire" - 6/12/2015 11:15:00 AM
Cancer Stocks: 2 to Sell, 1 to Buy "The Motley Fool" - 6/10/2015 10:05:06 AM
ARIAD and Paladin Announce Commercial Distribution Agreement for Iclusig (Ponatinib) in Canada "Business Wire" - 6/10/2015 7:35:00 AM
ARIAD Et Laboratoires Paladin Annoncent La Signature D’une Entente De Distribution Commerciale D’iclusig (Ponatinib) Au C... "Business Wire" - 6/10/2015 7:35:00 AM
ARIAD to Present at the Goldman Sachs Annual Global Healthcare Conference "Business Wire" - 6/8/2015 7:35:00 AM
ARIAD Presents Updated Clinical Data on brigatinib in Patients with ALK+ Non-Small Cell Lung Cancer at the 2015 ASCO Meeting "Business Wire" - 6/1/2015 9:00:00 AM
ARIAD Announces Long-Term Safety & Efficacy Data Of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical... "Business Wire" - 5/31/2015 9:00:00 AM
iandy Member Level  Friday, 07/12/13 07:16:59 AM
Re: jaybe post# 32123
Post # of 65234 
A relevant excerpt from the patent application:

>There is no cure for PD. Current therapy relies heavily on replenishing dopamine by giving patients oral doses of a dopaminergic agent like the dopamine precursor levodopa (alone or in the combination carbidopa levodopa) or a dopamine agonist. Such therapy can provide relief, although with the increasing risk of serious side effects and often with diminishing therapeutic results, requiring increasing doses as treatment continues, and more serious side effects. There is a profound need for additional therapeutics for PD.

c-Abl is a major regulator of parkin function and phosphorylates parkin on tyrosine 143. This phosphorylation inhibits parkin's E3 ubiquitin ligase activity leading to

accumulation of AIMP2 and FBP1 and loss of parkin's cytoprotective function and cell death. One Abl inhibitor, STI-571 , has been found to maintain parkin in a catalytically active and neuroprotective state by preventing phosphorylation of parkin. As such, it is believed that inhibition of c-Abl presents a viable approach for the treatment of PD. o, et al., PNAS, 107(38), 16691 -16696 (2010). One challenge of using STI-571 to treat PD is that it has poor penetration of the blood-brain barrier as demonstrated in mice and humans. Thus, there is a need for Abl inhibitors that cross the blood-brain barrier for the treatment of PD.

Applicant's own WO 2007/075869, which is hereby incorporated herein by reference for all purposes, discloses certain compounds that inhibit inter alia Abl. One notable Abl inhibitor is ponatinib, which is currently the subject of a clinical trial to determine the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with Ph positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or intolerant to either dasatinib or nilotinib, or have the T315I mutation of Bcr-Abl (clinical trials.gov identifier NCT01207440). WO 2007/075869 does not explicitly mention using such Abl inhibitors for the treatment of PD.

SUMMARY

It has been unexpectedly discovered that certain Abl inhibitors cross the blood brain barrier and are useful in the regulation of parkin and accordingly for the treatment of PD.<



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist